ABX vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ABX exhibits weak financial health per the Piotroski F-Score of 2/9, indicating significant operational and financial vulnerabilities. The absence of an Altman Z-Score raises distress risk concerns, especially given a dangerously low current ratio of 0.47 and a debt/equity ratio of 0.97. While the company shows explosive revenue growth (116.5% YoY) and strong margins, these are undermined by inconsistent earnings, negative historical EPS, and a lack of cash flow data. The stock trades at a premium to its Graham Number ($5.9) and intrinsic value ($2.52), suggesting overvaluation despite growth. Insider selling activity further signals caution.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
ABX vs JPM: Head-to-Head Comparison
This page compares Abacus Global Management, Inc. (ABX) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.